Following a sluggish start to the year, merger and acquisition activity in the biotechnology sector rebounded significantly in September and October 2025. The Trump administration's pressure on high drug prices and threats of imposing triple-digit tariffs on the pharmaceutical industry gradually subsided, while the initiation of an interest rate cycle further stimulated M&A deals. For instance, the high-profile bidding war between Pfizer (PFE.US) and Novo Nordisk (NVO.US) for Metsera and its leading weight-loss drug candidate vividly illustrates the intense competition in certain industry segments, as large pharmaceutical companies scramble to fill impending revenue gaps. A confluence of factors has contributed to the explosive growth in biotech M&A. Companies now face the dual challenge of replenishing their product pipelines while competing fiercely to acquire high-quality assets.

Some of the world's best-selling drugs risk losing patent protection in key regions, a phenomenon known within the industry as the "patent cliff." According to calculations, the loss of patent protection for top-selling brands will result in at least $173.9 billion in annual sales losses by 2032. Estimates for the total revenue at risk vary when smaller brands are included, with some analysts placing the figure between $200 billion and $350 billion. Unless these companies can replenish their R&D pipelines with new, revenue-generating innovative products, this poses a genuine threat to their income. Pharmaceutical companies need to supplement their pipelines, and simultaneously, after years of depressed valuations, the biotechnology industry is recovering, fueled by a healthcare investment boom during the COVID-19 pandemic.

M&A serves to fill the revenue gap. The unique aspect of the biopharmaceutical industry is that companies face patent expirations for their core assets approximately every decade. This asset lifecycle necessitates that companies continuously launch innovative products or acquire companies capable of doing so. "Biotechnology is the innovation engine in healthcare and has historically been the entry point for pharmaceutical companies to build their biopharma businesses," Linden Thomson, a senior portfolio manager at Candriam, told media. Many pharmaceutical companies started as chemical firms, often beginning with structurally simple small-molecule drugs, whereas biotech companies utilize living organisms to produce drugs like antibodies and mRNA.

Thomson noted that as pharmaceutical companies heavily invested in biotechnology, the lines between them have blurred, and many drugs on the market today were actually discovered or produced through biotechnology. The impending patent cliff is a major driver for M&A and a key component of the commercial strategy for many large pharmaceutical companies, including drugs like Bristol Myers Squibb's (BMY.US) Eliquis, Merck's (MRK.US) Keytruda, and Novo Nordisk's Ozempic nearing patent expiration. According to analysis by healthcare market research consultant Joanna Sadowska, approximately half of the blockbuster drugs approved between 2014 and 2023 were acquired rather than developed in-house. The two pharmaceutical companies with the highest number of blockbuster drug approvals during that period were Eli Lilly (LLY.US) and AstraZeneca (AZN.US), which acquired 8 out of 13 and 5 out of their respective drugs.

European pharmaceutical giants GSK (GSK.US) and Novartis (NVS.US) are clearly aware of the need to bolster their pipelines through acquisitions. Both companies are seeking "bolt-on deals" that align with their core therapeutic and technological areas. At an investor event in London in November, Novartis CEO Vasant Narasimhan emphasized the company's strong cash flow, "which allows us to really invest in business development." While Novartis did not specify the size of these bolt-on deals (having previously completed transactions up to $12 billion), GSK provided more concrete figures. Chris Sheldon, GSK's Global Head of Business Development, described it as the "optimal entry point": targeting validated biology, typically in mid-stage development, with investment amounts between $1 billion and $2 billion, a stage where the final outcome for a candidate drug remains uncertain.

Sheldon told media that acquisitions of many late-stage assets ultimately become mathematical exercises, especially when the target is publicly listed and valued at a reasonable level. He added, "I always liken business development to a contact sport. If an asset is good enough, there will be multiple companies bidding." Deal structures vary widely, ranging from collaborations, licensing, and royalty agreements to outright acquisitions. "If we could, we would license every day of the week rather than M&A, because licensing controls risk and rewards partners while unlocking value and de-risking," Sheldon said. However, sometimes an acquisition involving a large upfront payment might be the only option, and it offers enticing benefits, such as complete control over the R&D program and access to talent and the target molecule.

"In fact, the seller often holds the whip hand, something many people don't realize," Sheldon remarked. As biotech M&A heated up again, November witnessed what could be considered the industry's most notable event of the year: a public bidding war between Pfizer and Novo Nordisk for clinical-stage weight-loss drug maker Metsera, which Pfizer ultimately won with a deal valued up to $10 billion. Public bidding wars are not common, according to Stefan Loren, Managing Director at Oppenheimer & Co. "Chasing a company is a very public affair, so you have to worry about reputational damage: first, if you lose the bid; second, if you get too excited and buy recklessly. This undoubtedly reflects the state of the biotech market and the desire of companies to catch up. They are reacting to their circumstances, and their circumstance is that a lot of patents are expiring," Loren said.

Loren added that typically, frenzied bidding for drugs can last up to a year and a half before subsiding. In their early December report, the "2026 Healthcare Outlook," PitchBook researchers noted that the GLP-1 class of weight-loss drugs has become one of the most competitive segments globally in pharma, with major players racing to secure next-generation assets through both internal R&D and acquisitions. The report further added that over 60 companies are currently developing more than 120 metabolic drugs, providing a rich pool of potential M&A targets. "The high-profile battle between Pfizer and Novo Nordisk for Metsera underscores the growing strategic urgency in this area. We expect competition to intensify as differentiation narrows and policy tailwinds emerge," they stated.

While the obesity space effectively showcases the current competitive landscape, the biotech boom is not confined to a single therapeutic area. Neurology, oncology, immunology, and inflammation are other key active areas. "What's in vogue, at any given time, is in the eye of the beholder. They [companies] are looking for products that can fill the pipeline as quickly as possible," Loren said. The biotech sector has experienced boom, bust, and then boom again in recent years. During the COVID-19 pandemic, the biotech industry quickly became a hot pick for investors. Fueled by increased attention, high investor optimism, and low interest rates, the sector flourished, valuations soared, and many biotech companies successfully went public or were acquired by larger firms.

Because the biopharmaceutical industry is a high-cost R&D sector, raising capital is crucial for drug development. Early-stage biotech companies carry significant risk and often become early victims in risk-averse markets, such as the period following the pandemic boom. For much of 2025, the Trump administration also cast a shadow over the biopharma industry's prospects with threats of high tariffs, cuts to federal health agency budgets, and lower drug prices. But as companies reached agreements with Trump on pricing and the U.S. President made it clear they could be exempt from additional tariffs if they invested in U.S. manufacturing, two major overhangs for the sector were removed.

A series of positive data readouts have also pushed biotech stock valuations higher, Loren indicated. He said that just a year ago, even good data could cause stock prices to fall, as people used any news as an opportunity to sell. By late spring, the market began to shift, and now, investors are investing based on solid data. "When these metrics get to such low levels, where is the ultimate risk? And now, with M&A activity accelerating, the good news is that this investment thesis has become very real," Loren stated. Analysts suggest that deal volume is likely to increase further in 2026. PitchBook analysts said, "We believe 2026 will present one of the best investment opportunities we have seen in decades, primarily driven by the removal of U.S. healthcare policy uncertainty and further interest rate cuts, stimulating more speculative investment behavior."

Rajesh Kumar, Head of European Life Sciences and Healthcare Equity Research at HSBC, similarly anticipates a "significant increase" in deal volume in the coming year as the noise around drug pricing subsides. Kumar said, "Market expectations for margins beyond [2026] might be overly optimistic, but nonetheless, these companies are deploying capital in the U.S., manufacturing is booming, the landscape is clear—this is an excellent environment for actually doing biotech deals and early-stage biotech financing." Other developments in the pharmaceutical industry could present another year of significant headwinds for the drugmakers, potentially intensifying their urgency to make deals.

HSBC analysts noted that under the U.S. Inflation Reduction Act, price reductions for certain best-selling drugs will begin in 2026. The Act appears to treat active ingredients of drugs produced by the same manufacturer as identical, which in some cases limits lifecycle management options for drugs. Furthermore, the launch of biosimilars in the U.S. could also become easier if recent draft guidance from the U.S. Food and Drug Administration (FDA) is implemented. The analysts stated, "All these factors could mean that the market erosion post the patent cliff, especially for biologics, could be faster than in the past."